MedTrace Logo

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2023-02-28

No results posted yet for this study

Summary

This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical center's specialty outpatient clinic.

Conditions

  • Clostridium Difficile Infection
  • Clostridium Difficile Infection Recurrence

Interventions

BIOLOGICAL

Bezlotoxumab

Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment

DRUG

Standard CDI treatment

Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse

Sponsors & Collaborators

Principal Investigators

  • Eric R Wenzler, PharmD · University of Illinois at Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2023-02-22
Completion
2023-02-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04317963 on ClinicalTrials.gov